Not yet taking people in GermanyPhase 1
Skepinone-L added to sorafenib for advanced liver cancer not caused by viruses
Tests Skepinone-L with sorafenib in adults with advanced hepatocellular carcinoma.
Key facts
- Who runs it
- Universitaetsklinikum Tuebingen AöR
- Where
- Tuebingen, GermanySee the site
- Trial code
- Registry title
- A phase I, open-label, dose-escalation, safety, pharmacokinetic/-dynamic and clinical activity study of p38α inhibitor Skepinone-L to enhance therapeutic efficacy of Sorafenib in advanced hepatocellular carcinomas of non-viral origin
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 20 people, planned
- Starts
- 1 Dec 2026
- Expected to end
- 31 Jul 2032
- Type of study
- Interventional
- Record updated
- 29 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced hepatocellular carcinoma (a liver cancer) that was not caused by a virus. It tests Skepinone-L together with Sorafenib.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced hepatocellular carcinoma of non-viral origin
Where in Germany
- Universitaetsklinikum Tuebingen AöRTuebingen, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Skepinone-L added to sorafenib for advanced liver cancer not caused by virusesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 29 September 2026